Biofrontera, Inc. Hits New 52-Week High of $1.59, Surging 62.77%

Biofrontera, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 1.59 on August 26, 2026. This achievement marks a notable increase from its 52-week low of USD 0.55, reflecting a robust performance over the past year with a gain of 62.77%. Despite being a loss-making entity, Biofrontera's market capitalization stands at USD 10 million, positioning it within the microcap category. The company currently does not offer a dividend, and its debt-to-equity ratio is reported at -0.14, indicating a unique financial structure. Additionally, the return on equity is notably low at -109.12%, while the price-to-book ratio is recorded at 0.91. The stock's performance significantly outpaces the S&P 500, which has seen a return of 18.71% over the same period. This recent high underscores Biofrontera's evolving market position within the competitive landscape of the pharmaceuticals and biotechnology industry.